ArticleScientific reports2026
A Rho GTPase-related gene signature predicts prognosis and reveals an immunosuppressive microenvironment in lung adenocarcinoma: an integrated analysis of bulk and single-cell RNA sequencing data.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Lung adenocarcinoma (LUAD) is a malignancy characterized by significant heterogeneity and variable clinical outcomes. RhoGTPases play a critical role in cancer progression; however, their precise effects on LUAD prognosis remain inadequately understood. This study aimed to construct and validate a RhoGTPase-driven prognostic signature for LUAD, alongside an examination of its biological relevance. Transcriptomic and single-cell RNA sequencing (scRNA-seq) data were obtained from public databases. Candidate genes were identified by intersecting differentially expressed genes (DEGs) with a set of 733 RhoGTPase-related genes. Prognostic genes were selected through univariate Cox regression and least absolute shrinkage and selection operator (LASSO) analysis. A prognostic model was developed and subsequently validated. Analyses including functional enrichment, immune infiltration, and drug sensitivity were conducted. Additionally, scRNA-seq analysis was employed to define key cellular populations and explore the dynamic expression of the prognostic genes. A total of 5,420 DEGs were identified, yielding 233 candidate genes upon intersection with the RhoGTPase-related gene set. Four genes (CCT6A, PLK1, DSG2, PCDH7) were designated as prognostic. The risk model effectively stratified patients into the high-risk group (HRG) and the low-risk group (LRG), revealing significant differences in overall survival rates. The risk score served as an independent prognostic indicator. Functional enrichment analysis showed that HRG was associated with cell cycle pathways, while LRG was predominantly enriched in immune-related pathways, with HRG exhibiting a more immunosuppressive microenvironment. Drug sensitivity analysis indicated potential responsiveness to specific agents, such as doramapimod, in HRG. ScRNA-seq analysis identified epithelial cells as the primary population of interest. Pseudotime analysis uncovered a developmental trajectory in which CCT6A, DSG2, and PCDH7 were associated with late-stage, differentiated epithelial cell states. A robust prognostic model based on four RhoGTPase-related prognostic genes (CCT6A, PLK1, DSG2, PCDH7) was established, effectively stratifying LUAD patients. This model provides valuable insights into the heterogeneity of LUAD and has the potential to inform personalized therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.